Marksans Pharma Share Price

Marksans Pharma Limited is a pharmaceutical company headquartered in Mumbai. Its primary focus is on over-the-counter (OTC) and prescription drugs with diverse applications in fields such as oncology, gastroenterology, antidiabetic, antibiotics, cardiovascular, pain management and gynaecology.

The market capitalisation of Marksans Pharma is over ₹7,300 crore as of January 11, 2024. Marksans Pharma share price has gained over 160% in the last three years.

Business operations

Marksans Pharma focuses on the distribution of pharmaceutical products and is actively involved in research and development (R&D). It provides contract research and manufacturing services (CRAMS) to global pharmaceutical companies. The company’s R&D capabilities include dossier development services, formulation development and specialised drug delivery systems.

In the domestic market, the company’s speciality division concentrates on oncology and critical care therapy, with Markparin and Epigrof being its most popular brands. Epigrof is also supplied to hospitals and other institutes specialising in burns and trauma care. The company has a cerebella division that specialises in marketing drugs for lifestyle diseases, neurology and psychiatric therapy.

Its primary markets include the US, Europe, Canada, Australia and emerging markets such as Southeast Asia, Africa, Latin America and Russia. Its product portfolio consists of over 500 registered products in these regions. These international operations have grown over the years due to mergers and acquisitions by the company.

Marksans Pharma acquired Nova Australasia Pty Ltd. (Nova) in 2005. Nova is an Australian marketing company specialising in the promotion of over-the-counter and pharmaceutical products. Following this, in 2008, Marksans expanded its portfolio through the acquisition of the UK's Hale Group, inclusive of its subsidiary company Bell, Sons & Co. (Druggists) Ltd. (Bell). In the same year, the company acquired Relonchem Ltd. This company is actively involved in the licensing, marketing and distribution of generic pharmaceutical products in the UK.

The company has a portfolio of more than 50 FDA-approved products. In the UK, it offers a diverse range of over 100 products under the Bells Healthcare brand and another 160 products under its Relonchem brand.

Marksans Pharma operates three manufacturing units located in different regions: Goa, the UK and the USA. In Farmingdale, USA, the company can produce 6 billion tablets and hard capsules annually. Meanwhile, the Southport unit in the UK contributes to the production of 2 billion bottles, 1 billion tubes and 1 billion sachets per year. In Goa, the manufacturing capabilities include 2.4 billion softgel and hard gelatin capsules annually, along with the production of 6 billion solid tablets per year. The plant in Goa is spread over 18,000 square metres.

In addition to its manufacturing facilities, Marksans Pharma Limited has four research and development (R&D) centres located in Goa, Navi Mumbai, the UK and the USA.

Marksans Pharma Financial Highlights

• Revenue: Marksans Pharma reported revenue of ₹3,033.47 crore in FY26 vs ₹2,689.18 crore in FY25. It showed an increase of 12.80% on a yearly basis.
• Operating Profit: Marksans Pharma reported an operating profit of ₹560.56 crore in FY26 vs ₹503.97 crore in FY25. It showed an increase of 11.23% on a year-on-year basis.
• Net Profit: Marksans Pharma reported a net profit of ₹420.06 crore in FY26 vs ₹382.62 crore in FY25. It showed an increase of 9.79% on a yearly basis.

Marksans Pharma Quarterly Result Highlights

• Marksans Pharma reported revenue of ₹891.28 crore in Mar 2026, compared with ₹774.57 crore in Dec 2025, representing an increase of 15.07% on a quarter-on-quarter (QoQ) basis.
• Marksans Pharma reported an operating profit of ₹200.00 crore in Mar 2026, compared with ₹150.62 crore in Dec 2025, representing an increase of 32.78% on a quarter-on-quarter (QoQ) basis.
• Marksans Pharma reported a profit of ₹149.03 crore in Mar 2026, compared with ₹113.69 crore in Dec 2025, reflecting an increase of 31.08% on a QoQ basis.
• The earnings per share (EPS) of Marksans Pharma stood at ₹8.40 during Mar 2026.